慢性移植物抗宿主病的初始治疗:实践差异与无失败生存分析
该研究纳入3项观察性研究中745例接受初始系统免疫抑制治疗的cGVHD患者,分析初始治疗方案及泼尼松剂量与实践差异对结局的影响。多因素分析显示初始治疗组别及泼尼松剂量均与无失败生存、总生存或非复发死亡无关。 contemporary实践中初始治疗存在异质性,但未与上述结局相关。
要点
- 初始治疗包括非泼尼松免疫抑制(18%)、单用泼尼松(55%)及泼尼松联合其他免疫抑制(26%)。
- 泼尼松剂量分层为<0.25(9%)、0.25-0.74(36%)、0.75-1.25(42%)、>1.25 mg/kg/天(13%)。
- 初始治疗组别及泼尼松剂量均与FFS、OS、NRM无显著关联。
核心结论
- 当代cGVHD初始治疗实践存在异质性,包括泼尼松剂量和非类固醇方案的使用。
- 这种实践差异未与无失败生存、总生存或非复发死亡相关。
研究设计与样本
- 队列研究,纳入来自3项既往cGVHD Consortium观察性研究的745例接受初始系统免疫抑制治疗的cGVHD患者。
主要发现
- 初始治疗为非泼尼松免疫抑制137例(18%)、单用泼尼松411例(55%)、泼尼松联合其他免疫抑制197例(26%)。
- 泼尼松剂量<0.25 mg/kg/天占9%,0.25-0.74占36%,0.75-1.25占42%,>1.25占13%。
- 多因素分析中初始治疗组别与FFS、OS、NRM均无显著关联。
- 泼尼松剂量与FFS、OS、NRM均无显著关联。
- 总体cGVHD严重程度与初始治疗组别或泼尼松剂量之间未检测到显著交互作用。
临床怎么用
- 当前实践对cGVHD初始治疗的选择存在较大差异,但本观察性数据未显示不同初始方案或泼尼松剂量影响FFS、OS或NRM。
- 需前瞻性试验验证减量泼尼松或无泼尼松初始治疗方案的疗效。
局限性
- 为观察性研究,不能排除混杂因素。
- 需前瞻性试验验证减量泼尼松或无泼尼松初始治疗方案的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior clinical trials largely considered prednisone 1 mg/kg per day with or without calcineurin inhibitor as standard initial therapy for chronic graft-versus-host disease (cGVHD), but uncertainty remains regarding the extent of practice variation and whether this affects subsequent outcomes. We assembled a cohort of 745 patients with cGVHD treated with initial systemic immune suppressive (IS) therapy from 3 prior cGVHD Consortium observational studies. Initial therapy was defined as first IS therapy started for cGVHD or prednisone increased to ≥0.4 mg/kg per day from lower doses within 30 days before cGVHD diagnosis to any time afterward. Initial therapies were nonprednisone IS therapies (n = 137, 18%), prednisone alone (n = 411, 55%), or prednisone plus other IS therapy (n = 197, 26%). In multivariate analysis, initial therapy group was not associated with failure-free survival (FFS; a composite of death, relapse, and new IS therapy), overall survival (OS), or nonrelapse mortality (NRM). Among the prednisone-based approaches, steroid dose was <0.25 (9%), 0.25 to 0.74 (36%), 0.75 to 1.25 (42%), or >1.25 mg/kg per day (13%). Prednisone dose within the patients treated with steroids was not significantly associated with FFS, OS, or NRM. No significant interactions were detected between overall cGVHD severity and either initial therapy group or prednisone dose for the outcomes of FFS, OS, or NRM. These observational data document heterogeneity in more contemporary cGVHD initial treatment practices, including prednisone dose and use of nonsteroid approaches. This variation was not associated with FFS, OS, or NRM. Prospective trials are needed to verify efficacy of reduced-dose prednisone or prednisone-free initial therapy approaches.
引用
- Pidala J, Onstad L, Martin PJ, et al. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. Blood Adv. 2021. PMID: 34535015. doi:10.1182/bloodadvances.2021005286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。